안녕하세요.

퍼스트성모안과입니다.

 

이진해 원장이 세계의 망막 의사들이 가장 즐겨보고 진료에 참고하는 학술지인

"Retina" 의 논문 심사의원으로 초청받아 심사를 마쳤습니다.

 

 

 

 

 

 

·다국적 제약회사 임상연구 참여

 

- 2011– 2013

A Phase-3. Multi-center, Randomized, Double-masked, Sham-controlled Study of the Efficacy, Safety, and Tolerability

of intravitreal VEGF Trap-Eye in Subjects with Choroidal neovascularization Secondary to Pathologic Myopia. (MYRROR study, Bayer)

 

- 2012 – 2013

A Randomized, Sham Controlled, Multicenter, Double-Masked, Phase 2/3 Study Assessing Efficacy

and Safety of Betamethasone Microsphere in patients with macular edema following branch retinal vein occlusion -Phase II/III Confirmatory Study. (HIKARI Study, Santen)

 

- 2012 – 2015

A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab

in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis. (The EYEGUARD-A study, Servier)

 

- 2012 – 2015

A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab

in the Treatment of Subjects with Non infectious Intermediate, Posterior, or Pan- uveitis Currently Controlled with Systemic Treatment (EYEGUARD-C study, Servier)

 

- 2013 – 2017

A 24-month, phase IV, randomized, double masked, multi-center study of ranibizumab monotherapy

or ranibizumab in combination with verteporfin photodynamic therapy on visual outcome in patients with symptomatic macular polypoidal choroidal vasculopathy (EVEREST II Study, Novartis)

 

- 2013 – 2015

Unraveling nAMD real life clinical management and outcome with intravitreal ranibizumab injection – A retrospective analysis.

       (UNCOVER Study, Novartis)

 

- 2013 – 2015

A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy

and safety of 0.5 mg ranibizumab intravitreal injections in patients with visual impairment due to vascular endothelial growth factor (VEGF) driven macular edema (ME). (Novartis)

 

- 2013 – 2015

A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy

and safety of 0.5 mg ranibizumab intravitreal injections in patients with visual impairment due to vascular endothelial growth factor (VEGF) driven choroidal neovascularization (CNV). (Novartis)

 

- 2013 – 2016

Study to observe the effectiveness and safety of ranibizumab through individualized patient treatment and associated outcomes (LUMINOUS study, Novartis)

 

- 2014 – 2016

A 12-month, phase IIIb, randomized, visual acuity assessor-masked, multicenter study assessing the efficacy

and safety of ranibizumab 0.5mg in treat and extend regimen compared to monthly regimen, in patients with neovascular age-related macular degeneration (Novartis)

 

- 2014 – 2017

A randomized, double-masked, sham-controlled phase 3b/4 study of the efficacy, safety,and tolerability

of intravitreal aflibercept monotherapy compared to aflibercept with adjunctive photodynamic therapy as indicated in subjects with polypoidal choroidal vasculopathy.

Short title: Aflibercept in polypoidal choroidal vasculopathy. (PLANET Study, Bayer)

 

 

퍼스트성모안과는 국제적인 학술교류를 통하여

환자분들에게 최적의 치료가 무엇인지에 대해 지속적으로 노력하고 고민할 것입니다.

대학병원이나 전문병원의 긴 대기시간 없이 퍼스트성모안과에서

황반변성, 황반질환, 당뇨망막병증, 망막 혈관질환 등과 같은 

전문 망막질환의 진단 및 치료가 One-day로 가능합니다.

 

퍼스트성모안과의 망막 클리닉, 이진해 원장은

한국 백내장 굴절 수술학회, 한국 망막학회, 한국 포도막학회,

미국 시과학연구회, 미국 안과학회 등에서 정회원으로 활동중이며

 

Retina 저널의 논문 심사의원을 맡고 있습니다.

가입 시 까다로운 조건을 통과해야하는

미국 안과학회 및 한국 망막학회 정회원으로도

                                                                                            활동중인 망막 전문의, 포도막 전문의 입니다.

 

 

 

 

검증된 실력과 경험에서 나오는 노하우로

환자분들의 눈을 지켜드리는 퍼스트성모안과가 되겠습니다.

 

예약문의 02.6956.8011